drugset / Trial / NCT06576765

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

NCT06576765

Phase 1 Completed 16 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of AZD0780 with moderate and possibly mild hepatic impairment in comparison to a matched healthy control group.

Timeline

Start
2024-08-08
Primary completion
2024-11-08
Completion
2024-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Laroprovstat Small molecule Oral

Indications

No indication recorded.